Credit Suisse’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,678
| Closed | -$300K | – | 4540 |
|
|
2020
Q3 | $300K | Sell |
5,678
-600
| -10% | -$37K | ﹤0.01% | 3652 |
|
|
2020
Q2 | $384K | Buy |
+6,278
| New | +$363K | ﹤0.01% | 3464 |
|
|
2019
Q2 | – | Sell |
-3,957
| Closed | -$247K | – | 4296 |
|
|
2019
Q1 | $247K | Buy |
+3,957
| New | +$262K | ﹤0.01% | 3693 |
|
|
2017
Q4 | – | Sell |
-5,258
| Closed | -$245K | – | 4297 |
|
|
2017
Q3 | $245K | Buy |
+5,258
| New | +$252K | ﹤0.01% | 3841 |
|
|
2017
Q2 | – | Sell |
-6,534
| Closed | -$358K | – | 4017 |
|
|
2017
Q1 | $358K | Sell |
6,534
-2,851
| -30% | -$151K | ﹤0.01% | 3460 |
|
|
2016
Q4 | $523K | Sell |
9,385
-1,462
| -13% | -$70.3K | ﹤0.01% | 3419 |
|
|
2016
Q3 | $495K | Buy |
10,847
+568
| +6% | +$22.8K | ﹤0.01% | 3426 |
|
|
2016
Q2 | $411K | Buy |
10,279
+4,090
| +66% | +$150K | ﹤0.01% | 3531 |
|
|
2016
Q1 | $216K | Sell |
6,189
-1,836
| -23% | -$67.4K | ﹤0.01% | 3655 |
|
|
2015
Q4 | $345K | Buy |
+8,025
| New | +$402K | ﹤0.01% | 3616 |
|
|
2015
Q3 | – | Sell |
-5,428
| Closed | -$280K | – | 4576 |
|
|
2015
Q2 | $280K | Buy |
+5,428
| New | +$231K | ﹤0.01% | 4056 |
|
Other funds holding BSTC
Credit Suisse's BSTC Position: Q4 2020 in Review
Credit Suisse sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 5,678 shares — an estimated $300K sold.
Credit Suisse first reported a position in BSTC in Q2 2015 and held it in 11 quarters. The position peaked at $523K in Q4 2016. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Credit Suisse reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Credit Suisse sold 5,678 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $300K.
- Credit Suisse first reported a position in BioSpecifics Technologies Corp. in Q2 2015 and held it in 11 quarters.
- Credit Suisse's BioSpecifics Technologies Corp. position peaked at $523K in Q4 2016.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.